Pioneering medicine with the power to prevent
Siolta Therapeutics is a clinical-stage biotech company on a mission to alleviate the suffering of millions impacted by chronic inflammatory diseases through novel microbiome-based medicines. They leverage their deep knowledge of the developing infant gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases. Their blended expertise from microbiology, immunology, and bioinformatics supports the development of a multifaceted platform, integrating ecosystems approaches and precision medicine concepts to advance the future of medicine. Currently focused on the clinical development of their lead product for the prevention and treatment of allergic asthma, Siolta’s holistic, microbiome-based strategy represents a new frontier in the pursuit of tailored, clinically differentiated microbial therapeutics.
To develop microbiome-based therapeutics and diagnostics aimed at the prevention and treatment of chronic inflammatory diseases, beginning with asthma.See more